Key Points
- FDA posts pouch environmental review;
- Covers “other” nicotine products;
- Agency says impacts are minimal;
- Assessment may affect PMTA reviews.
2Firsts
May 21, 2026
As of May 21, 2026 ET, The U.S. Food and Drug Administration (FDA) released a Programmatic Environmental Assessment covering nicotine pouches and other nicotine products categorized as “other.”
FDA said the assessment is part of its review process for Premarket Tobacco Product Applications (PMTAs), which requires the agency to evaluate the environmental effects of authorizing new tobacco products for sale.
Products included in the “other” category covered by the assessment include:
- nicotine pouches;
- lozenges;
- nicotine tablets;
- nicotine gums;
- dissolvable tobacco products;
- and other nicotine-infused products.
However, FDA specifically excluded traditional smokeless tobacco products such as:
- dip;
- snuff;
- snus;
- and chewing tobacco.
According to the agency, existing scientific evidence suggests these products generally have “minimal” environmental effects.
FDA explained that because these products do not produce airborne emissions during use, they can reduce or eliminate:
- secondhand exposure;
- and thirdhand exposure.
The agency also said waste generated from these products contains relatively few harmful chemicals that:
- leach into the environment;
- persist over time;
- or bioaccumulate.
FDA said publication of the environmental assessment is part of its broader commitment to regulatory transparency.
The agency added that the document may also be cited by FDA scientific reviewers during future PMTA evaluations.
FDA emphasized that although the assessment broadly applies to the “other” product category, each tobacco product application will still be reviewed individually based on the specific evidence submitted.
Under FDA procedures, when a new tobacco product receives authorization, the agency typically publishes:
- an Environmental Assessment;
- a Finding of No Significant Impact (FONSI);
or
- an Environmental Impact Statement.
The U.S. nicotine pouch market has continued expanding rapidly in recent years.
Major brands including PMI’s ZYN, Altria’s on!, and Reynolds American’s VELO continue increasing their presence in the market.
Industry observers said the environmental assessment signals that FDA is continuing to refine its regulatory framework for nicotine pouches and other oral nicotine products.
Analysts added that while the document does not itself authorize products for sale, it may influence future PMTA review processes, regulatory expectations, and industry planning.
(Cover Image source: FDA)
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
